HomeCompareDMPWW vs SCHD

DMPWW vs SCHD: Dividend Comparison 2026

DMPWW yields 2000000.00% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMPWW wins by $1.6247481716182984e+23M in total portfolio value
10 years
DMPWW
DMPWW
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full DMPWW calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — DMPWW vs SCHD

📍 DMPWW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMPWWSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMPWW + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMPWW pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMPWW
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, DMPWW beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMPWW + SCHD for your $10,000?

DMPWW: 50%SCHD: 50%
100% SCHD50/50100% DMPWW
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMPWW buys
0
SCHD buys
0
No recent congressional trades found for DMPWW or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMPWWSCHD
Forward yield2000000.00%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$1.6247481716182984e+23M$29.0K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$425.95
Total dividends collected$1.6146053563276882e+23M$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: DMPWW vs SCHD ($10,000, DRIP)

YearDMPWW PortfolioDMPWW Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,226$346.36+$100.00MDMPWW
2$467,446,731,075$467,339,719,626.17$12,572$357.38+$467446.72MDMPWW
3$1,021,215,363,816,662$1,020,715,195,814,411.90$14,046$367.84+$1021215363.80MDMPWW
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$15,660$377.73+$1043112617104.09MDMPWW
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$17,425$387.07+$498482143759731.38MDMPWW
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$19,354$395.86+$111599275650097776.00MDMPWW
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$21,461$404.13+$11738678336351557632.00MDMPWW
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$23,762$411.89+$583674362697175072768.00MDMPWW
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$26,272$419.15+$1.3894210989607547e+22MDMPWW
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$29,010$425.95+$1.6247481716182984e+23MDMPWW

DMPWW vs SCHD: Complete Analysis 2026

DMPWWStock

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Full DMPWW Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this DMPWW vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMPWW vs JEPIDMPWW vs ODMPWW vs KODMPWW vs MAINDMPWW vs VYMDMPWW vs DGRODMPWW vs VIGDMPWW vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.